Results from a follow-up study of the Myeloma X trial revealed that the presence of high-risk lesions could diminish the benefit of ASCT.
Researchers found that survival was associated with the number of metastatic sites, but not affected by brain metastasis.
Evidence suggests that starting on systemic drug therapy immediately may be the best approach for some patients with metastatic RCC.
Three specific subtypes of multiple myeloma were found to drive higher incidence rates among individuals of African descent.
Genomic and proteomic studies of medulloblastoma samples helped researchers characterize new cancer subtypes and targets.
Immunotherapy may supplant sunitinib in RCC, except for in patients who cannot tolerate checkpoint inhibition.
The combinatorial approach is not, furthermore, limited to chemotherapy.
